Videos
Emerging Biomarkers for Monitoring Remyelination in Multiple Sclerosis: Ahmed Abdelhak, MD
June 4th 2025The assistant professor of neurology at the University of California, San Francisco discussed current advancements and ongoing challenges in identifying biomarkers to accurately monitor remyelination in MS clinical trials. [WATCH TIME: 5 minutes]
Understanding the Causes of Duchenne Muscular Dystrophy
June 4th 2025A panelist discusses how steroid use in DMD patients provides significant benefits in delaying disease progression, particularly loss of ambulation, despite potential side effects including mood disorders, bone weakness, and weight gain.
Clinical Application and Potential of Cognitive Amyloid Risk Measure: James Galvin, MD, MPH
June 4th 2025The professor of neurology at the Miami Miller School of Medicine detailed the clinical potential of Cognivue’s Amyloid Risk Measure (CARM) for identifying individuals with cognitive impairment likely related to amyloid pathology. [WATCH TIME: 5 minutes]
NeuroVoices: Kathy Zackowski, PhD, OTR, on Promoting Psychosocial Wellness Research in MS Care
June 4th 2025The associate vice president of research at National MS Society talked about the need for evidence-based wellness strategies in multiple sclerosis, particularly focusing on psychosocial interventions.
Individualizing Disease-Modifying Therapy Selection in Newly Diagnosed MS: Gabrielle Macaron, MD
June 3rd 2025The assistant professor in the Department of Neuroscience at Université de Montréal discussed key clinical factors influencing DMT selection in patients newly diagnosed with multiple sclerosis. [WATCH TIME: 5 minutes]
Treatment and Diagnosis of MOG-Associated Disorders in Pediatric vs Adult: E. Ann Yeh, MD
June 2nd 2025The professor of pediatrics in neurology at the University of Toronto discussed differences in disease course, treatment strategy, and trial challenges of MOG-associated disorders in pediatric versus adult patients. [WATCH TIME: 5 minutes]
Hypertension Awareness Gaps in Patients With Multiple Sclerosis: Michael Robers, MD, MS
June 2nd 2025The assistant professor of neurology at Barrow Neurological Institute talked about the lack of public awareness for hypertension among individuals with MS despite many meeting diagnostic criteria. [WATCH TIME: 6 minutes]
Starting Comprehensive Multiple Sclerosis Care at Initial Diagnosis: Mary R. Rensel, MD, FAAN, ABIHM
May 31st 2025The associate professor of medicine at the Cleveland Clinic Lerner College of Medicine highlighted the importance of early, multidisciplinary intervention for patients with multiple sclerosis. [WATCH TIME: 3 minutes]
Identifying and Treating Progression in MS Beyond Relapses: Celia Oreja-Guevara, MD, PhD
May 30th 2025The vice chair of neurology at the Hospital Clínico San Carlos in Madrid highlighted the growing importance of detecting and managing progression in multiple sclerosis, particularly PIRA. [WATCH TIME: 6 minutes]
Why Choose a DORA? Clinical Considerations for Patients With Insomnia
May 30th 2025A panelist discusses how clinicians choose between sleep aids like dual orexin receptor antagonists (DORAs) and other medications based on patient comorbidities, chronicity of insomnia, and adverse effect profiles, with DORAs offering a safer, long-term solution for patients with chronic insomnia and sleep maintenance issues.
Challenges in and Advice for Prescribing Subcutaneous Infusion Systems for Parkinson Disease
May 30th 2025Panelists discuss how challenges in prescribing subcutaneous infusion systems might affect patient adherence and device management, best practices for patient education, and what additional data would benefit clinicians implementing newer Parkinson disease treatments.
From Trials to Treatment: Understanding the Treatment Profile of Daridorexant
May 30th 2025A panelist discusses how dual orexin receptor antagonists (DORAs) are effective for treating both sleep initiation and maintenance insomnia, with a generally favorable adverse effect profile, though patients should be informed about potential risks like parasomnia-like behaviors, and the importance of patience and adherence for optimal results.
Emerging Therapies and Valuable Insights for Facilitating REST in Epilepsy
May 30th 2025A panelist discusses how midazolam autoinjectors provide an effective, fast-acting solution for rapid eye seizure termination (REST) in emergency settings, emphasizing the importance of proper education, timely use, and monitoring for adverse effects such as sedation or respiratory depression.
Clinical Pearls for CIDP Management
May 29th 2025Panelists discuss how physicians can improve outcomes for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) by prioritizing early and accurate diagnosis, personalizing treatment plans, regularly monitoring patients, and addressing the psychological and emotional impact of the disease.
Place of Recent Approvals in Parkinson Disease Management
Panelists discuss how recent approvals of novel delivery systems are reshaping the treatment landscape for Parkinson disease by addressing unmet needs in managing motor fluctuations.
Clinical Experience With CSAI for Parkinson Disease
Panelists discuss how their clinical experience with continuous subcutaneous infusion therapies has informed their approach to integrating these treatments into existing regimens, including strategies for medication adjustments and valuable lessons from European clinical practice that could benefit US clinicians.
